Physician profile
Tanzila Bashar
NPI 1952757213
$367.49
in general payments reported to CMS, 2019-2025
10 companies · $38.14 in 2025
The $38.14 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.29 · 2023: $101 · 2024: $131 · 2025: $38.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $112.04 | 2022-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $68.46 | 2023-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Glaxosmithkline, LLC. | $63.37 | 2022-2024 | Bexsero |
| Biomarin Pharmaceutical INC. | $22.85 | 2025 | Voxzogo 1.2mg |
| Verrica Pharmaceuticals INC. | $19.24 | 2024 | Ycanth |
| Avion Pharmaceuticals | $17.47 | 2023 | Methylphenidate Hydrochloride |
| Corium, LLC | $17.23 | 2022 | |
| Ironshore Pharmaceuticals INC. | $16.26 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.29 | 2025 | |
| Cranial Technologies, INC | $15.28 | 2023 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanzila Bashar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.